Creutzfeldt-Jakob disease (CJD) is diagnosed through a combination of clinical symptoms, brain imaging, spinal fluid tests, and brain wave recordings. No single test confirms CJD in a living patient. The only way to reach a definite diagnosis is through examination of brain tissue, which typically happens after death. For living patients, doctors classify the diagnosis as “probable” or “possible” based on how many diagnostic criteria are met.
Getting to that probable diagnosis is rarely straightforward. In a study of 97 patients with sporadic CJD, the average person received 3.8 different misdiagnoses before CJD was identified. The mean time from first symptoms to diagnosis was 7.9 months, roughly two-thirds of the way through their disease course. The most common initial misdiagnoses included viral encephalitis, paraneoplastic disorders, depression, vertigo, and Alzheimer disease.
Why CJD Is So Hard to Identify
CJD causes rapidly progressive dementia, but so do dozens of other conditions. Before a doctor can even consider CJD, they need to rule out a long list of alternatives: vascular problems like stroke, infections, autoimmune conditions such as Hashimoto’s encephalopathy, cancers that affect the brain, vitamin deficiencies (B12, thiamine), liver or kidney dysfunction, and metal toxicity. The University of California San Francisco uses the mnemonic VITAMINS to organize these categories: Vascular, Infectious, Toxic-metabolic, Autoimmune, Metastases/neoplasm, Iatrogenic, Neurodegenerative, and Systemic.
This extensive workup is a required part of reaching a probable CJD diagnosis. Blood tests, imaging, and sometimes additional biopsies are used to cross each alternative off the list. Only when those investigations don’t point to another explanation do doctors move forward with CJD-specific testing.
MRI Brain Scans
MRI has become one of the most important tools for identifying CJD during life. The key technique is diffusion-weighted imaging (DWI), which detects changes in how water moves through brain tissue. In CJD, DWI reveals a distinctive pattern called “cortical ribboning,” where ribbon-like bright areas appear along the surface of the brain. These bright signals can also show up in deep brain structures called the caudate nucleus and putamen.
For a probable diagnosis, MRI needs to show high signal in the caudate or putamen, or in at least two cortical regions (temporal, parietal, or occipital lobes). These patterns can appear relatively early in the disease and help distinguish CJD from other causes of rapid cognitive decline. A standard MRI sequence called FLAIR can also pick up these changes, though DWI is generally more sensitive.
Variant CJD Looks Different on MRI
Variant CJD, the form linked to mad cow disease, produces a distinct MRI pattern. Instead of cortical ribboning, it shows bright signal in the back part of the thalamus, a deep brain structure. This finding is called the “pulvinar sign.” A related pattern, the “hockey-stick sign,” involves bright signal in both the pulvinar and the neighboring dorsomedial thalamic nuclei. These thalamic patterns are sensitive and specific markers for variant CJD, and they help distinguish it from the sporadic form. One important nuance: young patients with sporadic CJD can occasionally show some pulvinar brightness, but in those cases, the signal intensity stays lower than in the front part of a structure called the putamen.
The RT-QuIC Spinal Fluid Test
The most significant diagnostic advance in recent years is a spinal fluid test called RT-QuIC (Real-Time Quaking-Induced Conversion). This test detects the misfolded prion protein that causes CJD by using a small sample of spinal fluid to “seed” a reaction. If misfolded prions are present, they cause normal proteins in the test solution to misfold and clump together, producing a measurable signal.
RT-QuIC has a sensitivity of 92% and a specificity of 100%, based on analysis of over 1,600 samples at the UK National CJD Research and Surveillance Unit. That 100% specificity is particularly important: it means a positive result is extremely reliable. A negative result doesn’t completely rule out CJD, since the test misses about 8% of cases, but a positive RT-QuIC combined with appropriate symptoms is now sufficient for a probable diagnosis on its own. The CDC criteria state that a neuropsychiatric disorder plus a positive RT-QuIC in spinal fluid meets the threshold for probable sporadic CJD.
The 14-3-3 Protein Test
Before RT-QuIC became widely available, the 14-3-3 protein test in spinal fluid was the primary laboratory marker for CJD. This protein leaks into the spinal fluid when brain cells are rapidly destroyed. It has a sensitivity of about 92%, similar to RT-QuIC, but its specificity is only around 80%. That gap matters. False positives occur in other conditions that cause rapid brain cell loss, including stroke, encephalitis, and other forms of dementia.
The 14-3-3 test remains part of the CDC diagnostic criteria, where a positive result counts toward a probable diagnosis in patients whose symptoms have lasted less than two years. But its limitations are well recognized. A positive result in someone who doesn’t otherwise fit the clinical picture should prompt consideration of other diagnoses, not lock in a CJD conclusion. The test works best when a doctor already has moderate-to-high suspicion of CJD based on other findings, roughly a 20% to 90% pre-test probability. Another spinal fluid marker, total tau protein, performs comparably to 14-3-3 and is sometimes tested alongside it.
EEG Brain Wave Patterns
An electroencephalogram (EEG) can detect a pattern called periodic sharp wave complexes, which are characteristic of CJD. These are repetitive, high-voltage electrical discharges that fire at regular intervals. Finding this pattern on EEG counts as one of the laboratory criteria for probable sporadic CJD.
The limitation is timing. These periodic discharges typically don’t become obvious until 8 to 12 weeks after symptoms begin, and in some cases even later. Early in the disease, a standard EEG reading may look normal or show only nonspecific slowing. Advanced computational techniques can extract subtle periodic patterns from raw EEG data as early as 3 to 5 weeks after onset, but these methods aren’t part of routine clinical practice. It’s also worth noting that the classic EEG pattern is not seen in variant CJD, making this test useful mainly for the sporadic form.
What Counts as a Probable Diagnosis
The CDC defines probable sporadic CJD through two possible pathways. The simpler path requires any neuropsychiatric disorder plus a positive RT-QuIC test in spinal fluid or other tissue. The second path requires rapidly progressive dementia plus at least two of four clinical features: sudden involuntary muscle jerks (myoclonus), visual or balance problems, movement abnormalities, or a late-stage state of unresponsiveness called akinetic mutism. On top of those clinical signs, at least one laboratory test must also be positive: a characteristic EEG, a positive 14-3-3 test (if symptoms have lasted under two years), or characteristic MRI findings. In all cases, routine workup must not suggest a different diagnosis.
Definite Diagnosis Requires Brain Tissue
A definite diagnosis of CJD can only be made by examining brain tissue under a microscope. This involves identifying the misfolded prion protein through specialized staining techniques, Western blot testing, or finding structures called scrapie-associated fibrils. In practice, this almost always happens through autopsy after death. Brain biopsy during life is technically possible but rarely performed because the risks are significant, the disease has no treatment, and modern testing with RT-QuIC and MRI can reach a probable diagnosis with high confidence.
Autopsy confirmation remains valuable for surveillance purposes and for families seeking certainty. It also helps distinguish CJD subtypes, which can carry different implications for genetic counseling if the case turns out to involve a hereditary form.